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Introduction
Since their discovery, stem cells have altered the per  cep-
tion of the human body and revolutionized medical 
research. Th  e understanding of how the human body 
develops and repairs itself has improved [1]. Because of 
this, we are able to expand upon the possibilities of stem 
cell use within the human body. As a result, interest in 
stem cells as therapies has increased [1].
Research into the use of stem cells for the treatment of 
neurodegenerative diseases, such as Alzheimer disease 
(AD), Parkinson disease (PD), amyotrophic lateral 
sclerosis (ALS), and multiple sclerosis (MS), has become 
a growing interest in the medical community. Each of 
these diseases aﬀ  ects diﬀ  erent areas and structures of the 
central nervous system (CNS). An extensive initiative to 
investigate stem cells as possible treatments for these 
four diseases has occurred. Stem cells hold a great oppor-
tunity for each of these diseases as a form of replacement 
or protective therapy. Although this is not meant to be an 
all-inclusive review of current stem cell research within 
neurodegenerative disease, we review the major 
opportunities and obstacles stem cells hold for the future 
of treatments for AD, PD, ALS, and MS.
Stem cells and their opportunities and limitations
Stem cells were discovered in the early 1960s [2,3], and 
knowledge about their characteristics and composition 
has come a long way. Stem cells are generally deﬁ  ned as 
cells that are capable of self-renewal and that possess the 
ability to diﬀ  erentiate into multiple types of cells. On the 
basis of their diﬀ  erentiation abilities, stem cells can be 
classiﬁ  ed as totipotnet, pluripotent, or multipotent. Toti-
potent stem cells are capable of diﬀ  erentiating into any 
type of cell within the body, including extra-embryonic 
tissue, and can be isolated from only the four-cell stage of 
the embryo. Isolated from the blastocyst of the embryon, 
pluripotent stem cells are capable of diﬀ  erentiation into 
any cell within the body, and so they are able to give rise 
to cells from any of the three major tissue lineages: 
ectoderm, mesoderm, and endoderm. Multipotent stem 
cells are capable of diﬀ  erentiation into only the select 
types of cells from which they are derived and can be 
isolated from various sources within the adult human 
body. As the human body develops, the margin of 
diﬀ   erentiation capability begins to be reduced from a 
totipotent state to a pluripotent state and lastly to a 
multipotent capability.
Naturally occurring stem cells generally include 
embryonic stem cells (ESCs), fetal stem cells (FSCs), and 
adult stem cells. Obtained from the blastocyst, ESCs are 
pluripotent and proliferate quite well in culture. Given 
these two qualities, ESCs appear to oﬀ  er both a signiﬁ  -
cant number of cells and the ability to germinate into a 
variety of diﬀ  erent cell types [4]. ESCs have the most 
ability to be used in a clinical setting since they are able to 
give rise to multiple types of cells; however, there are 
multiple ethical concerns with their use [5,6] and the risk 
of adverse reactions, such as an immune reaction or 
tumor formation or both [7].
As a source of multipotent stem cells, fetal organs 
contain FSCs. Th   e several advantageous qualities of FSCs 
include their adaptability to their environment, migration 
capabilities, lack of teratoma formation, and rejections in 
vivo [8].
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cells, which are deﬁ  ned by their tissue of origin. Multiple 
areas within the adult body, including bone marrow, 
muscle, brain, and liver, contain an endogenous adult 
stem cell population [1]. Th  e key beneﬁ  t of adult stem 
cells is their potential use in autologous therapies, in 
which cells can be harvested and used within the same 
patient. Th  is  beneﬁ  t eliminates the ethical concerns and 
risks that ESCs bear. As advantageous as adult stem cells 
appear to be, the limited diﬀ  eren  tiation ability restricts 
universal use within the body.
Because naturally occurring stem cells have limitations, 
scientists have developed a method for increasing 
pluripotency within non-pluripotent cells. Th   e latter cells 
are termed induced pluripotent stem (iPS) cells, and 
multiple studies cite the reprogramming process that 
uses speciﬁ  c transcription factors, such as Oct4,  Sox2, 
Klf4, and c-Myc, to induce pluripotency [9-12]. Some 
argue that the use of only two of these factors is suﬃ   cient 
for iPS cell formation [13,14]. iPS cells open up the 
possibility of using a patient’s own somatic cells, through 
reprogramming, for treatment. However, iPS cells have 
limitations as well. First, the process of creating these 
types of cells is low in eﬃ   ciency [15]. Th   e fact that a large 
number of starting cells are needed for the reprogram-
ming process makes this a challenging beginning. 
Second, the use of viruses for transduction of the 
pluripotency factors within iPS cells poses a problem of 
possible integration into the host genome if these factors 
become reactivated [16]. Lastly, iPS cells have the ability 
the produce teratomas, although the risk is less signiﬁ  -
cant compared with ESCs [16]. Researchers have attemp-
ted to address these disadvantages. Th   e low eﬃ   ciency of 
reprogramming iPS cells may be related to the p53-
mediated DNA damage [17], and so inhibiting p53 may 
increase the conversion of the cells but may increase the 
risk of tumorigenesis from iPS cells as well. Th  e  second 
issue has been attacked in two ways. One is to use non-
viral transfection [18], although the eﬃ   cacy still needs to 
be worked out and long-term control of the gene 
expression may be diﬃ   cult. Another approach would be 
the use of Cre-recombinase excisable viruses [19] or 
delivery of recombinant protein [20]. However, we still 
must prove the functionality and safety of the resulting 
cells, and stem cell-based therapy may still have hurdles 
to overcome but its future is very promising.
Stem cells and neurodegenerative diseases
Neurodegenerative diseases hold an opportunity for the 
clinical use of stem cells. In neuroscience, the discovery 
of neural stem cells (NSCs) and subsequent research [21] 
have nulliﬁ  ed the previous idea that the adult CNS was 
not capable of neurogenesis [22,23]. Indeed, neurogenesis 
occurs throughout life. NSCs are believed to reside 
within the subventricular zone of the lateral ventricle 
wall and the subgranular zone of the hippocampal 
dentate gyrus, where neurogenesis occurs [22,24]. NSCs 
give rise to glial-restricted precursors (GRPs) and neuron-
restricted precursors, both of  which diﬀ  erentiate  into 
astrocytes, oligodendrocytes, or neurons [23]. Another 
study demon  strated that transplanted NSCs isolated 
from a 9-week-old human fetus have the ability to 
diﬀ  erentiate into neural cells and improve cognition in 
aged rats [25]. Hence, the idea of using NSCs for 
neurodegeneration treatment is intriguing.
However, NSCs are not so easy to access as a source of 
stem cells for possible use to treat neurodegenerative 
diseases. Previously, many studies have suggested the use 
of bone marrow-derived mesenchymal stem cells (MSCs) 
for regeneration of neural cells since MSCs are present in 
bone marrow and are relatively easily accessible within 
the human body. However, the consen  sus now is that 
naive MSCs do not become neural cells. Our previous 
study suggests that MSCs can be de  diﬀ  erentiated into 
cells similar to iPS cells by increasing the expression of a 
single ESC gene, nanog. We were able to transdiﬀ  erentiate 
MSCs into neural cell lineage after dediﬀ  erentiation. Th  is 
result indicates that we may be able to use adult stem 
cells as an autologous source to create iPS cells. Th  is 
technology and iPS cells together may oﬀ  er the potential 
for autologous neuroregenerative therapies to be 
developed along with the ease of access to a patient’s own 
cells. Another key factor for the develop  ment of stem cell 
treatments for neurological diseases will be the under-
standing of the pathology of the speciﬁ  c disease. Each 
disease will need to be assessed individually and each 
treatment will need to be tailored accordingly.
Alzheimer disease
As one of the most common causes of dementia, AD 
aﬀ  ects 5.3 million Americans [26]. AD, known for its 
quint  essential hallmarks of amyloid-β peptide (Aβ) 
plaques and neuroﬁ  brilary tangles [21,27-29], results in 
the death of several types of neuronal lineage cells within 
multiple regions of the brain [29-31], speciﬁ  cally 
cholinergic neurons [23]. Discovered in 1987, the human 
amyloid precursor protein (APP) gene is located on 
chromosome 21 and codes for a type I transmembrane 
protein [32]. Aβ plaques are generated by γ- and β-
secretases that cleave APP at speciﬁ  c amino acids [33], 
and neuroﬁ  brilary tangles are composed of tau proteins 
that are hyper-phosphorylated, resulting in neuron impair-
ment [34]. Both of these hallmarks lead to cognitive 
impairment and loss of memory [29]. However, the direct 
pathogenesis of AD still eludes researchers [35].
Currently available drugs for the treatment of AD are 
purely for symptoms [36] and among these drugs are the 
cholinesterase inhibitors [33,37]. After acetylcholine is 
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its degradation, leading to improved cognition [33]. 
However, these types of drugs have only a modest eﬀ  ect, 
which can be variable among patients [38]. Another type 
of drug available for AD patients is an N-methyl-d-
aspartate (NMDA) receptor antagonist named meman-
tine [33]. Memantine prevents the NMDA receptors 
from overstimulation that can lead to toxicity [33]. Since 
the current treatments have only marginal eﬀ  ects and 
greatly vary in their eﬀ  ectiveness in patients, the need for 
new treatments is great. It is estimated that there will be 
615,000 new cases by 2029 and 959,000 by 2050 [26]. 
Owing to this increase in the number of new cases, a 
great burden will be placed on health-care systems [26]. 
Th  e need for a proper treatment or cure for AD is 
imperative.
Recently, Blurton-Jones and colleagues [29] published a 
study in which they injected NSCs into the hippocampal 
regions of the brain of both a transgenic AD mouse 
model and an age-matched non-transgenic mouse model. 
Interestingly, the mice improved in cognitive function 
and there was no change to the existing Aβ plaques or 
neuroﬁ   brilary tangles [29]. Instead, the authors dis-
covered brain-derived neurotrophic factor, which is 
important for neuron outgrowth, and synapse formation 
increased [39], leading to improved cognition through 
increased synaptic density [29]. Th   is demonstrated cog-
ni  tion could be improved without the need for modifying 
the existing pathological conditions [29].
Although the physiological function of APP is not clear, 
recent reports indicate that it may play an important role 
in regulating stem cell biology or adult neurogenesis [40]. 
We found that APP increased chemokine levels to alter 
cell migration [41]. We also showed that increased APP 
caused glial diﬀ  erentiation of human NSCs in vitro and in 
vivo. Th   is may create the problem of how to regenerate 
neurons by augmentation of NSCs when APP levels are 
high. Also, increased levels of APP, found in Down 
syndrome patients, who develop AD in later life, may 
exhaust endogenous NSC populations because of 
increased premature glial diﬀ  erentiation of the cells [42]. 
Th  is APP function may need to be considered for 
neuroregenerative therapies under a pathogenic APP 
environment within the AD brain. Increased levels of 
APP in the brain not only reduce NSCs, which may 
increase the risk of AD, but also increase the level of glial 
diﬀ  erentiation of stem cells upon transplantation, reduc-
ing the eﬃ   cacy of therapy to improve cognitive function 
[42,43]. Th   us, the levels of APP may need to be reduced 
before transplantation of stem cells, and our previous 
study showed signiﬁ  cant neurogenesis from NSC trans-
plantation in APP transgenic mice but only after APP 
level was reduced by phenserine treatment [34]. NSCs 
may also be useful to augment growth factors. A 
trans  genic model of AD showed improvement in cogni-
tion by release of BDNF (brain-derived neuro  trophic 
factor) after NSCs [29]. NSCs are also reported to express 
neuro  trophic factors and promote axonal growth in 
spinal cord injury [44].
Many experimental studies show a beneﬁ  cial neuro-
protective eﬀ  ect of hemopoietic growth factors such as 
granulocyte colony-stimulating factor (G-CSF), erythro-
poietin (EPO), granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF), stem cell factor, vascular endo-
thelial growth factor (VEGF), and stromal cell-derived 
factor-1-alpha (SDF-1-alpha) in ischemic stroke [45,46]. 
Bone marrow-derived MSCs are reported to protect or 
reduce ischemic damage by releasing insulin-like growth 
factor-1 (IGF-1) in transient ischemic model animals. 
Furthermore, NSCs modiﬁ  ed by transfection of vascular 
endothelial growth factor provided neuro  protection after 
transient focal cerebral ischemia [47]. Despite promising 
results from animal models, the lack of data in humans 
hampers eﬃ     cacy assessments of growth factors on 
neurodegenerative disease therapy. In clinical study with 
stroke patients, MSC-treated patients showed signiﬁ  cant 
and consistent improvement in the Barthel index and 
modiﬁ  ed Rankin score over the control patients during 
the follow-up period up to 12 months [48]. More recently, 
a long-term follow-up study of intravenous autologous 
MSC transplantation in patients with ischemic stroke 
showed very promising results [49]. Th  ese results may 
support the use of stem cells to augment growth factor in 
AD in the future.
Parkinson disease
First described in 1817, PD, the second most common 
neurodegenerative disease [50], is a neurological de-
gener  a  tive disease that results in the loss of dopaminergic 
neurons within the substantia nigra [51,52], leading to a 
loss of motor function. Lewy body formation and neuritis 
are the pathological hallmarks of this disease, and the 
speciﬁ  c etiology is still unknown [52]. PD itself is not 
fatal but complications from the disease can lead to 
death.
Current treatments for PD include drug regimens and 
surgery. However, these treatments are purely palliative. 
Th   e current drug treatment for PD supplies the surviving 
dopamine neurons with l-Dopa, which they convert to 
dopamine [53]. Eventually, however, all of the remaining 
dopamine neurons die and treatment with l-Dopa is 
ineﬀ  ective [53].
MSCs have been proposed as a potential treatment for 
PD. Park and colleagues [54] investigated the use of 
MSCs in a PD mouse model to observe a potential neuro-
protective eﬀ   ect on neuronal loss. MSCs signiﬁ  cantly 
preserved the number of dopaminergic neurons and 
tyrosine hydroxlase-positive cells in vitro and in vivo [54]. 
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the use of adult olfactory stem cells for recovery of 
dopaminergic neurons in PD. Th  e adult olfactory stem 
cells were diﬀ  erentiated into NPCs and were capable of 
becoming dopaminergic-like neurons both in vitro and in 
vivo [55]. NSCs have also been investigated for their use 
as possible treatments for PD. Yasuhara and colleagues 
[56] tested the use of NSCs on the behavioral beneﬁ  ts 
and protective eﬀ  ects in PD in vivo. When NSCs were 
immediately transplanted after 6-hydroxydopamine lesion 
formation in mice, tyrosine hydroxlase neurons were 
protected and PD symptoms were reduced [56].
Th   e study of Kim and colleagues [57] supports the use 
of ESCs for cell replacement therapy as the authors have 
shown that highly enriched populations of midbrain 
NSCs can be derived from mouse ESCs. Th  e dopamine 
neurons generated by these stem cells show electro-
physiological and behavioral properties expected of 
neurons from the midbrain [57]. To move forward with 
these studies, further experiments must be developed to 
show methods of enriching  the cell of interest and 
demonstrate that these cells show functions that will 
assist in treating the disease.
Other studies have investigated the use of iPS cells, 
derived from mouse ﬁ   broblasts, to produce neural 
progenitor cells, which are multi  potent adult stem cells, 
for injection into 6-hydroxy  dopamine-lesioned rats [58]. 
Th   e injected derived iPS cells were capable of migration 
to various areas of the brain, diﬀ  erentiated into glia and 
neurons, and integrated into the host brain [58]. 
Additionally, the eﬃ   ciency of their experiment was high, 
and almost all of the animals showed high numbers of 
tyrosine hydroxlase-positive cells [58]. Th  e study of 
Iacovitti and colleagues [59] supports this by deriving 
midbrain dopaminergic (mDA) neurons from a commer-
cially available human induced pluripotent stem (hiPS) 
cell line, IMR90 clone 4. Th  e authors were able to 
produce cells that followed the same lineage pathway as 
H9 human ESCs and that showed the same expression 
levels of dopamine and DOPAC (dihydroxyphenylacetic 
acid) [59]. Th  e mDA hiPS cells that were transplanted 
into 6-OHDA-leisioned PD rats not only survived in the 
long term but also integrated into the host brain, but it 
was also noted that many Nestin+ tumor-like cells 
remained at the site of graft [59]. Th  e future success of 
cell replacement therapies for PD will depend on the 
ability to select the appropriate mDA cell lineage.
Amyotrophic lateral sclerosis
ALS, also known as Lou Gehrig’s disease, is a neuro-
degenerative disease aﬀ  ecting the spinal cord and brain 
stem and typically is adult-onset. Speciﬁ  cally, the upper 
and lower motor neurons die, leading to progressive 
paralysis [60]. Over 150 years ago, the classic hallmarks 
of this disease, including the death of motor neurons and 
progressive atrophy, were des  cribed [50]. Generally, the 
mean onset age is 55 years, and prognosis after diagnosis 
is only 2 to 5 years [50]. Th  e cause of ALS is still 
unknown.
In 2006, Chi and colleagues [61] performed a study that 
observed the role of neural progenitor cells in an ALS 
disease mouse model. Interestingly, the degeneration of 
the motor neurons stimulated neurogenesis and neural 
progenitor cell proliferation [61]. In another study, Corti 
and colleagues [62] transplanted NSCs positive for both 
Lewis X and a chemokine receptor into the spinal cord. 
Disease progression was delayed and survival time 
increased for transplanted mice because of an integration 
of the transplanted cells into the spinal cord [62]. Th  ese 
studies may indicate that neurotropic factors produced 
by transplanted stem cells protect neurons from the 
environment of ALS and increase neurogenesis. Since 
abnormality of astrocytes is one of the hallmarks of ALS, 
replacement of glia cells by adult glial progenitors [63] 
and GRPs [64] has been proposed. Studies by Maragakis 
and colleagues [63] and Rothstein and colleagues [64] 
show that astrocyte dysfunction occurs in human ALS 
and SOD1G93A animal models. Th  e authors showed 
success in transplantation of lineage-restricted astrocyte 
precursors, GRPs. GRPs not only survived in the diseased 
environment but also diﬀ  erentiated into astrocytes and 
reduced microgliosis in SOD1G93A rat cervical spinal cord 
[64]. Th  ese  ﬁ  ndings demonstrate the potential ability for 
transplantation-based astrocyte replacement and show 
that cell transplantation to the cervical spinal cord is a 
promising therapeutic strategy for slowing focal motor 
neuron loss associated with ALS [64]. Th  ese preclinical 
animal studies are promising and may develop into 
clinical applications in the near future. On the other 
hand, replacement of degenerating motor neurons may 
create some controversy because of the lack of knowledge 
of whether the patients’ cells produce healthy motor 
neurons and the ability of these cells to survive under the 
pathological condition. A recent study gives us an 
optimistic view of the development of neuroregeneration 
therapy of ALS. Dimos and colleagues [65] successfully 
produced motor neurons from iPS cells derived from an 
82-year-old patient with familial ALS.
In 2008, Mazzini and colleagues [66] published a 
clinical-based experiment in which MSCs were autolo-
gously transplanted to ALS patients through a spinal cord 
injection. Th   e authors state that the results of this study 
show that MSCs are safe for clinical use for treatment of 
ALS and showed a slowing in the decline in the forced 
vital capacity and functional rating scores of some 
patients [66]. However, as the study notes, this experi-
ment was performed on a small number of patients and 
will need to be replicated with a large number of patients 
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did replicate this experiment with a larger number of 
patients, publishing the results in 2010. Although similar 
results were obtained, the study lacked signiﬁ  cant 
changes in the progression of the disease, which were 
obtained in the previous study [67].
Multiple sclerosis
One of the major qualities of MS, a CNS autoimmune 
disease, is the initial relapse-remitting cycle of the 
disease, eventually leading to progression of the disease 
without relapses [68]. Th  e myelin sheath, the primary 
target, is degraded and this degradation aﬀ  ects neurons 
[50]. Unlike AD, PD, and ALS, MS predominately aﬀ  ects 
young adults and has a higher rate of occurrence in 
females [50]. MS is also a heterogeneous disease, and so 
the degree of the disease can range from fairly benign to 
extremely debilitating and the stages of disease can range 
from only relapses to progressive [68]. Again, currently 
available treatments are purely symptomatic.
Current approaches for MS treatment include mono-
clonal antibodies, chimeric molecules, and hemato  poietic 
stem cells (HSCs) [69]. Th   e general aim of HSCs for MS 
treatment is to completely correct the immune system 
anomaly within the patient [69]. A study by Aharonowiz 
and colleagues [70] investigated the use of human ESC-
derived neural precursor cells into the cerebral ventricles 
of an MS mouse model. Th  e transplanted human ESC-
derived neural precursor cells reduced the clinical signs 
of MS and had a neuroprotective eﬀ   ect by immuno-
suppression within the mice [70].
Th  e use of myelin-forming cell transplantation to 
restore myelin at sites of myelin loss has been 
experimented with since the 1970s [71]. However, the 
myelin-forming cells, especially those cells that are 
linage-restricted, are very limited in their growth and 
ability to regenerate myelin [71]. Th  erefore, stem cells 
might hold the answer for cell transplant treatments in 
MS [71]. In 2009, Burt and colleagues [72] published a 
study in which non-myeloablative HSCs were autolo-
gously transplanted to relapse-remitting MS patients. 
Neurological improvement and a slowing in progression 
were observed after transplantation [72].
Conclusions
Clinical application of stem cells, whether ESCs, FSCs, 
adult stem cells, or iPS cells, is increasingly becoming a 
reality. However, great care will need to be taken when 
moving forward. Th   e pathological environments of 
neuro  degenerative diseases will need to be assessed to 
observe their eﬀ  ect on transplanted stem cells. Addition-
ally, the migratory patterns of transplanted stem cells will 
need to be observed and possibly controlled. With 
movement toward clinical use of stem cells, protocols 
will have to undergo extensive scrutiny of their preclinical 
safety and beneﬁ  t analyses, projected experiments, and 
informed consent protocols [73].
In 2008, the International Society for Stem Cell 
Research released a set of recommended guidelines for 
the development of stem cell-based treatments [74]. 
Th  ese recommendations include the use of experts in 
stem cell biology for peer review of research ranging 
from preclinical to clinical, emphasizing risks involved 
with stem cell-based therapies within the voluntary 
informed consent, new oversight criteria for medical 
innovative care that falls outside of the realm of a clinical 
trial, and the equality of beneﬁ  ts of stem cell treatments 
[74].
In regard to the number of clinical trials, the number of 
AD and PD versus ALS and MS clinical trials is highly 
skewed. Th  e reason for this perhaps is that, once their 
condition is diagnosed, ALS and MS patients have a 
limited prognosis. AD and PD patients have a longer 
prognosis. Potentially, the US Food and Drug Adminis-
tration is more inclined to initiate clinical trials for ALS 
and MS because of the risk-to-beneﬁ  t  relationship. 
However, an increase in clinical trails for AD and PD is 
inevitable because of the high cost of ‘human life’ these 
two diseases present, along with the ﬁ  nancial burden of 
cost of care.
Although the issues presented above do need to be 
resolved before the clinical application of stem cells can 
be realized, the advancement of these technologies is 
building. Th  e number of stem cell clinical trials will 
increase tremendously and conceivably some will become 
standard treatments.
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